Your browser doesn't support javascript.
Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort.
Appelman, Brent; Oppelaar, Jetta J; Broeders, Lani; Wiersinga, Willem Joost; Peters-Sengers, Hessel; Vogt, Liffert.
  • Appelman B; Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
  • Oppelaar JJ; The Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.
  • Broeders L; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Wiersinga WJ; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Peters-Sengers H; Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
  • Vogt L; The Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands.
Sci Rep ; 12(1): 2258, 2022 02 10.
Article in English | MEDLINE | ID: covidwho-1684108
ABSTRACT
Chronic kidney disease (CKD) has been recognized as a highly prevalent risk factor for both the severity of coronavirus disease 2019 (COVID-19) and COVID-19 associated adverse outcomes. In this multicenter observational cohort study, we aim to determine mortality and readmission rates of patients hospitalized for COVID-19 across varying CKD stages. We performed a multicenter cohort study among COVID-19 patients included in the Dutch COVIDPredict cohort. The cohort consists of hospitalized patients from March 2020 until July 2021 with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection with a CORADS score ≥ 4. A total of 4151 hospitalized COVID-19 patients were included of who 389 had a history of CKD before admission. After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX (kidney transplantation), odds ratios of death and readmission compared to patients without CKD ranged from 1.96 to 8.94. We demonstrate an evident increased 12-week mortality and readmission rate in patients with chronic kidney disease. Besides justified concerns for kidney transplant patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Readmission / Renal Insufficiency, Chronic / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-06276-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Readmission / Renal Insufficiency, Chronic / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-06276-7